Read More Pharma Industry News Dizal Pharmaceutical deepens NSCLC pipeline case as DZD6008 and golidocitinib data sharpen ASCO 2026 focus Read how Dizal’s ASCO 2026 NSCLC data for DZD6008 and golidocitinib could reshape its lung cancer pipeline strategy today! bySrinathMay 31, 2026